UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo´s (STO:ORXA) licensing partner for Rapinyl™in Europe, ProStrakan Group plc announces that Rapinyl™ has received Swedish Marketing Authorization. It is anticipated that the product branded as “Abstral” will be launched in Sweden in Q3 2008 through Orexo´s joint venture with ProStrakan, which operates in the Nordic countries.
